At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
bevacizumab +2 moredrug
Likely dose
bevacizumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center·interventional·Posted Feb 23, 2006·Updated Oct 20, 2020
In Brief
A Phase 2 clinical trial evaluating bevacizumab, cisplatin, and 1 other intervention for Mesothelioma. Completed, enrolled 53 participants across 1 site.
Detailed Summary
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma
CountriesUnited States
CollaboratorsUniversity of Chicago, Columbia University, Duke University
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionJun 2010
Study CompletionAug 2010
TodayJul 2026
First PostedFeb 23, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJun 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.4 years ago
Interventions
bevacizumabdrug
15 mg/kg IV every 3 weeks
cisplatindrug
75 mg/m2 IV every 3 weeks
pemetrexeddrug
500 mg/m2 every 3 weeks